NASDAQ:MGNX

Macrogenics Stock Insider Trading

Healthcare > Biotechnology

Buy MGNX

*Your capital is at risk

$4.69

+0.110 (+2.40%)

At Close: Jun 23, 2026

MacroGenics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 96.57. In total, the insiders bought 2.21M and sold 56.02K MGNX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	96.57
● Buy	2.21M shares
● Sell	56.02K shares
84% Buy Activity Moderate Negative Correlation
Buy Signal High Confidence Feb 12, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 96.57. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (84% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
May 19, 2026 Buy	Restricted Stock Unit A-Award	Stump David C Director	Director	3 750 Value: $17.0K
May 19, 2026 Buy	Restricted Stock Unit A-Award	Hurwitz Edward Director	Director	3 750 Value: $17.0K
May 19, 2026 Buy	Restricted Stock Unit A-Award	Chhabra Meenu Director	Director	3 750 Value: $17.0K
May 19, 2026 Buy	Stock Option (right to buy) A-Award	Chhabra Meenu Director	Director	22 000 Value: $99.4K
May 19, 2026 Buy	Restricted Stock Unit A-Award	Heiden William K Director	Director	3 750 Value: $17.0K
May 19, 2026 Buy	Stock Option (right to buy) A-Award	Heiden William K Director	Director	22 000 Value: $99.4K
May 19, 2026 Buy	Restricted Stock Unit A-Award	Jackson Scott Thomas Director	Director	3 750 Value: $17.0K
May 19, 2026 Buy	Stock Option (right to buy) A-Award	Jackson Scott Thomas Director	Director	22 000 Value: $99.4K
May 19, 2026 Buy	Restricted Stock Unit A-Award	O'brien Federica F. Director	Director	3 750 Value: $17.0K
May 19, 2026 Buy	Stock Option (right to buy) A-Award	O'brien Federica F. Director	Director	22 000 Value: $99.4K
May 19, 2026 Buy	Stock Option (right to buy) A-Award	Ferrante Karen Jean Director	Director	22 000 Value: $99.4K
May 19, 2026 Buy	Restricted Stock Unit A-Award	Ferrante Karen Jean Director	Director	3 750 Value: $17.0K
May 19, 2026 Buy	Stock Option (right to buy) A-Award	Liu Margaret Director	Director	22 000 Value: $99.4K
May 19, 2026 Buy	Restricted Stock Unit A-Award	Liu Margaret Director	Director	3 750 Value: $17.0K
May 19, 2026 Buy	Stock Option (right to buy) A-Award	Hurwitz Edward Director	Director	22 000 Value: $99.4K
May 19, 2026 Buy	Stock Option (right to buy) A-Award	Stump David C Director	Director	22 000 Value: $99.4K
May 19, 2026 Buy	Restricted Stock Unit A-Award	Koenig Scott Director	Director	3 750 Value: $17.0K
May 19, 2026 Buy	Stock Option (right to buy) A-Award	Koenig Scott Director	Director	22 000 Value: $99.4K
May 18, 2026 Buy	Restricted Stock Unit M-Exempt	Stump David C Director	Director	3 750 Value: $16.3K
May 18, 2026 Buy	Restricted Stock Unit M-Exempt	Hurwitz Edward Director	Director	3 750 Value: $16.3K
May 18, 2026 Buy	Restricted Stock Unit M-Exempt	Chhabra Meenu Director	Director	3 750 Value: $16.3K
May 18, 2026 Buy	Common Stock M-Exempt	Chhabra Meenu Director	Director	3 750 Value: $16.3K
May 18, 2026 Buy	Restricted Stock Unit M-Exempt	Liu Margaret Director	Director	3 750 Value: $16.3K
May 18, 2026 Buy	Restricted Stock Unit M-Exempt	Heiden William K Director	Director	3 750 Value: $16.3K
May 18, 2026 Buy	Common Stock M-Exempt	Heiden William K Director	Director	3 750 Value: $16.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT MACROGENICS

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The...

Read Full Profile Here